Labcorp Announces 2023 First Quarter Results

Company Updates Full-Year Guidance First quarter Base Business revenue grew 10%, while total revenue and earnings were down due to COVID-19 Testing Revenue: Q1 of $3.8 billion versus $3.9 billion last year Diluted EPS: Q1 of $2.39 versus $5.23 last year Adjusted EPS: Q1 of $3.82 versus $6.11 last

Fractionated dosing: A more clinically relevant approach to radiotherapy in preclinical tumor models

Development of a mutation profiling NGS assay to facilitate clinical decisions in hematologic malignancies

Genomic landscape of patients with non-small cell lung cancer

Enhanced detection and classification of cell-free DNA alterations through matched normal analyses with PGDx elio plasma complete

Complementary use of DNA- and RNA-based NGS assays optimizes detection of clinically relevant translocations for comprehensive genomic profiling

Inhibition of murine myeloid suppressor cells increases CD8+T cell activation in vitro

Preclinical assessment of chimeric antigen receptor (CAR) T persistence and functionality in the disseminated NALM6-Luc human B cell acute lymphoblastic leukemia (ALL) model

Transcriptional analysis of TME in MC38 colon carcinoma model following checkpoint inhibition